share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股sec公告 ·  04/25 16:38
Moomoo AI 已提取核心訊息
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has announced the completion of a 1-for-10 reverse stock split of its common stock, effective April 25, 2024. The reverse stock split was previously approved by the company's stockholders during a Special Meeting held on April 17, 2024, where they granted the board of directors the authority to determine the exact split ratio and timing. The board of directors subsequently approved the reverse stock split at the 1-for-10 ratio. Following the split, the common stock began trading on The Nasdaq Capital Market on a split-adjusted basis from market open on April 26, 2024. The par value and other terms of the common stock remain unchanged. The company's post-split common stock CUSIP number is 98987D 300. The amendment to the company's Second Amended and Restated Certificate of Incorporation, detailing the reverse stock split, was filed with the Secretary of State of Delaware and is included as Exhibit 3.1 in the current report.
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has announced the completion of a 1-for-10 reverse stock split of its common stock, effective April 25, 2024. The reverse stock split was previously approved by the company's stockholders during a Special Meeting held on April 17, 2024, where they granted the board of directors the authority to determine the exact split ratio and timing. The board of directors subsequently approved the reverse stock split at the 1-for-10 ratio. Following the split, the common stock began trading on The Nasdaq Capital Market on a split-adjusted basis from market open on April 26, 2024. The par value and other terms of the common stock remain unchanged. The company's post-split common stock CUSIP number is 98987D 300. The amendment to the company's Second Amended and Restated Certificate of Incorporation, detailing the reverse stock split, was filed with the Secretary of State of Delaware and is included as Exhibit 3.1 in the current report.
生物製藥公司ZyVersa Therapeutics, Inc. 宣佈完成其普通股的1比10反向拆分，自2024年4月25日起生效。反向股票拆分此前已在2024年4月17日舉行的特別會議上獲得公司股東的批准，他們在會上授權董事會確定確切的分拆比率和時間。董事會隨後批准了按1比10的比例進行反向股票拆分。拆分後，普通股從2024年4月26日開盤開始在納斯達克資本市場進行拆分調整後交易。普通股的面值和其他條款保持不變。該公司拆分後的普通股CUSIP號碼爲98987D 300。該公司第二次修訂和重述的公司註冊證書修正案詳細說明了反向股票拆分，已提交給特拉華州國務卿，並作爲附錄3.1包含在本報告中。
生物製藥公司ZyVersa Therapeutics, Inc. 宣佈完成其普通股的1比10反向拆分，自2024年4月25日起生效。反向股票拆分此前已在2024年4月17日舉行的特別會議上獲得公司股東的批准，他們在會上授權董事會確定確切的分拆比率和時間。董事會隨後批准了按1比10的比例進行反向股票拆分。拆分後，普通股從2024年4月26日開盤開始在納斯達克資本市場進行拆分調整後交易。普通股的面值和其他條款保持不變。該公司拆分後的普通股CUSIP號碼爲98987D 300。該公司第二次修訂和重述的公司註冊證書修正案詳細說明了反向股票拆分，已提交給特拉華州國務卿，並作爲附錄3.1包含在本報告中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息